Literature DB >> 24771638

Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis.

Roland S Croner1, Michael Stürzl, Tilman T Rau, Gergana Metodieva, Carol I Geppert, Elisabeth Naschberger, Berthold Lausen, Metodi V Metodiev.   

Abstract

We used high-resolution mass spectrometry to measure the abundance of more than 9,000 proteins in 19 individually dissected colorectal tumors representing lymph node metastatic (n = 10) and nonmetastatic (n = 9) phenotypes. Statistical analysis identified MX1 and several other proteins as overexpressed in lymph node-positive tumors. MX1, IGF1-R and IRF2BP1 showed significantly different expression in immunohistochemical validation (Wilcoxon test p = 0.007 for IGF1-R, p = 0.04 for IRF2BP1 and p = 0.02 for MX1 at the invasion front) in the validation cohort. Knockout of MX1 by siRNA in cell cultures and wound healing assays provided additional evidence for the involvement of this protein in tumor invasion. The collection of identified and quantified proteins to our knowledge is the largest tumor proteome dataset available at the present. The identified proteins can give insights into the mechanisms of lymphatic metastasis in colorectal carcinoma and may act as prognostic markers and therapeutic targets after further prospective validation.
© 2014 UICC.

Entities:  

Keywords:  MX1; biomarkers; colorectal cancer; drug targets; mass spectrometry; metastasis

Mesh:

Substances:

Year:  2014        PMID: 24771638      PMCID: PMC4192020          DOI: 10.1002/ijc.28929

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

1.  Normalization, testing, and false discovery rate estimation for RNA-sequencing data.

Authors:  Jun Li; Daniela M Witten; Iain M Johnstone; Robert Tibshirani
Journal:  Biostatistics       Date:  2011-10-14       Impact factor: 5.899

2.  The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications.

Authors:  Donald S Kirkpatrick; Scott A Gerber; Steven P Gygi
Journal:  Methods       Date:  2005-01-12       Impact factor: 3.608

3.  Mapping and quantifying mammalian transcriptomes by RNA-Seq.

Authors:  Ali Mortazavi; Brian A Williams; Kenneth McCue; Lorian Schaeffer; Barbara Wold
Journal:  Nat Methods       Date:  2008-05-30       Impact factor: 28.547

4.  Quantitative proteomics reveals subset-specific viral recognition in dendritic cells.

Authors:  Christian A Luber; Jürgen Cox; Henning Lauterbach; Ben Fancke; Matthias Selbach; Jurg Tschopp; Shizuo Akira; Marian Wiegand; Hubertus Hochrein; Meredith O'Keeffe; Matthias Mann
Journal:  Immunity       Date:  2010-02-18       Impact factor: 31.745

5.  IFN-alpha induced human 78 kD protein: purification and homologies with the mouse Mx protein, production of monoclonal antibodies, and potentiation effect of IFN-gamma.

Authors:  M A Horisberger; H K Hochkeppel
Journal:  J Interferon Res       Date:  1987-08

6.  Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data.

Authors:  Jun Li; Robert Tibshirani
Journal:  Stat Methods Med Res       Date:  2011-11-28       Impact factor: 3.021

Review 7.  Interferons, Mx genes, and resistance to influenza virus.

Authors:  M A Horisberger
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

8.  Cdc2 as prognostic marker in stage UICC II colon carcinomas.

Authors:  Alexander Meyer; Susanne Merkel; Wolfgang Brückl; Vera Schellerer; Claus Schildberg; Valentina Campean; Werner Hohenberger; Roland S Croner
Journal:  Eur J Cancer       Date:  2009-02-14       Impact factor: 9.162

Review 9.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

10.  One step nucleic acid amplification (OSNA) - a new method for lymph node staging in colorectal carcinomas.

Authors:  Roland S Croner; Vera Schellerer; Helene Demund; Claus Schildberg; Thomas Papadopulos; Elisabeth Naschberger; Michael Stürzl; Klaus E Matzel; Werner Hohenberger; Anne Schlabrakowski
Journal:  J Transl Med       Date:  2010-09-06       Impact factor: 5.531

View more
  9 in total

1.  A feature selection method for classification within functional genomics experiments based on the proportional overlapping score.

Authors:  Osama Mahmoud; Andrew Harrison; Aris Perperoglou; Asma Gul; Zardad Khan; Metodi V Metodiev; Berthold Lausen
Journal:  BMC Bioinformatics       Date:  2014-08-11       Impact factor: 3.169

2.  An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype.

Authors:  Ming-Kai Chuang; Yu-Chiao Chiu; Wen-Chien Chou; Hsin-An Hou; Mei-Hsuan Tseng; Yi-Yi Kuo; Yidong Chen; Eric Y Chuang; Hwei-Fang Tien
Journal:  Oncotarget       Date:  2015-11-17

3.  Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma.

Authors:  Kenta Mukaihara; Yoshiyuki Suehara; Shinji Kohsaka; Daisuke Kubota; Midori Toda-Ishii; Keisuke Akaike; Tsutomu Fujimura; Eisuke Kobayashi; Takashi Yao; Marc Ladanyi; Kazuo Kaneko; Tsuyoshi Saito
Journal:  BMC Cancer       Date:  2016-03-10       Impact factor: 4.430

4.  The mechanism of formation, structure and physiological relevance of covalent hemoglobin attachment to the erythrocyte membrane.

Authors:  Elizabeth M Welbourn; Michael T Wilson; Ashril Yusof; Metodi V Metodiev; Chris E Cooper
Journal:  Free Radic Biol Med       Date:  2016-12-20       Impact factor: 7.376

5.  Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.

Authors:  Abrar I Aljohani; Chitra Joseph; Sasagu Kurozumi; Omar J Mohammed; Islam M Miligy; Andrew R Green; Emad A Rakha
Journal:  Breast Cancer Res Treat       Date:  2020-04-29       Impact factor: 4.872

Review 6.  Molecular Network of Colorectal Cancer and Current Therapeutic Options.

Authors:  Zhe Huang; Mingli Yang
Journal:  Front Oncol       Date:  2022-04-06       Impact factor: 5.738

7.  Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination.

Authors:  Yi Wang; Chunzhao Li; Xiaohan Chi; Xijian Huang; Hua Gao; Nan Ji; Yang Zhang
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

8.  Decreased Usage of Specific Scrib Exons Defines a More Malignant Phenotype of Breast Cancer With Worsened Survival.

Authors:  Gergana Metodieva; Samson Adoki; Berthold Lausen; Metodi V Metodiev
Journal:  EBioMedicine       Date:  2016-05-07       Impact factor: 8.143

9.  Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.

Authors:  So Jeong Lee; Cheong-Soo Hwang; Young-Keum Kim; Hyun Jung Lee; Sang-Jeong Ahn; Nari Shin; Jung Hee Lee; Dong Hoon Shin; Kyung Un Choi; Do Youn Park; Chang Hun Lee; Gi Young Huh; Mi Young Sol; Hee Jin Lee; Gyungyub Gong; Jee Yeon Kim; Ahrong Kim
Journal:  Cancer Res Treat       Date:  2016-07-07       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.